Logo do repositório
 
Publicação

Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy

2021Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorGarcia‐Pavia, Pablo
dc.contributor.authorBengel, Frank
dc.contributor.authorBrito, Dulce
dc.contributor.authorDamy, Thibaud
dc.contributor.authorDuca, Franz
dc.contributor.authorDorbala, Sharmila
dc.contributor.authorNativi‐Nicolau, Jose
dc.contributor.authorObici, Laura
dc.contributor.authorRapezzi, Claudio
dc.contributor.authorSekijima, Yoshiki
dc.contributor.authorElliott, Perry M.
dc.date.accessioned2021-09-15T12:58:36Z
dc.date.available2021-09-15T12:58:36Z
dc.date.issued2021
dc.description© 2021 European Society of Cardiologypt_PT
dc.description.abstractTransthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening condition with a heterogeneous clinical presentation. The recent availability of treatment for ATTR-CM has stimulated increased awareness of the disease and patient identification. Stratification of patients with ATTR-CM is critical for optimal management and treatment; however, monitoring disease progression is challenging and currently lacks best-practice guidance. In this report, experts with experience in treating amyloidosis and ATTR-CM developed consensus recommendations for monitoring the course of patients with ATTR-CM and proposed meaningful thresholds and frequency for specific parameters. A set of 11 measurable features across three separate domains were evaluated: (i) clinical and functional endpoints, (ii) biomarkers and laboratory markers, and (iii) imaging and electrocardiographic parameters. Experts recommended that one marker from each of the three domains provides the minimum requirements for assessing disease progression. Assessment of cardiac disease status should be part of a multiparametric evaluation in which progression, stability or improvement of other involved systems in transthyretin amyloidosis should also be considered. Additional data from placebo arms of clinical trials and future studies assessing ATTR-CM will help to elucidate, refine and define these and other measurements.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEur J Heart Fail. 2021 Jun;23(6):895-905pt_PT
dc.identifier.doi10.1002/ejhf.2198pt_PT
dc.identifier.eissn1879-0844
dc.identifier.issn1388-9842
dc.identifier.urihttp://hdl.handle.net/10451/49520
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherJohn Wiley & Sons, Inc.pt_PT
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/journal/18790844pt_PT
dc.subjectAmyloidosispt_PT
dc.subjectCardiac imagingpt_PT
dc.subjectHeart failurept_PT
dc.subjectLaboratory markerspt_PT
dc.subjectMonitoring toolspt_PT
dc.subjectTransthyretin amyloid cardiomyopathypt_PT
dc.titleExpert consensus on the monitoring of transthyretin amyloid cardiomyopathypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage905pt_PT
oaire.citation.issue6pt_PT
oaire.citation.startPage895pt_PT
oaire.citation.titleEuropean Journal of Heart Failurept_PT
oaire.citation.volume23pt_PT
person.familyNameBrito
person.givenNameDulce
person.identifier.ciencia-idF216-586F-1762
person.identifier.orcid0000-0003-1278-1847
person.identifier.ridG-9650-2016
person.identifier.scopus-author-id7004510538
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication196a2934-1434-433c-9735-81acb6fbe587
relation.isAuthorOfPublication.latestForDiscovery196a2934-1434-433c-9735-81acb6fbe587

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Expert_consensus.pdf
Tamanho:
976.46 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM-CCUL-Artigos em Revistas Internacionais